CYTEA BIO is a Swiss/French pre-clinical stage biotech company dedicated to developing therapeutic antibody- effector cell constructs using its patented Pinā¢ Platform.
Our innovative approach combines Fc-engineered targeting ligands with genetically unmodified effector cells, enabling precise targeting, potentially enhancing treatment efficacy while reducing toxicity.
Product candidates in pre-clinical development
Years of academic research behind the platform
Potential combinations
our pinā¢ platform
CYTEA BIO is a preclinical-stage biotechnology company specializing in innovative ligand-driven immunotherapies that leverage unmodified allogeneic cells as effector entities. The company has developed and patented a versatile and modular therapeutic platform known as the Pinā¢ Platform.
pipeline
Lead program in EGFR+ glioblastoma
Robust pre-clinical data demonstrate strong cytotoxicity against target cells, highly potent inhibition of tumor growth, and excellent tolerability with no observed toxicity in animal models
Pre-arming of effector cells with Pinā¢ Platform transforms the ability of therapeutic cells to locate and engage targets, resulting in dramatically superior loading and efficiency of targeting ligands.
The versatility of the Pinā¢ Platform allows for customization to accommodate diverse tumor phenotypes, with rapid modifications of effector cells or ligands
Cytea Bio: Empowering effector cells
Our patented Pinā¢ Platform combines Fc-engineered targeting ligands with genetically unmodified allogeneic effector cells, allowing for precise targeting thus potentially improving treatment efficacy and reducing toxicity. Our key innovation involves modifying the Fc portion of ligands to significantly enhance their affinity for the CD16 receptor on effector cells. This modification enables the pre-arming of effector cells before patient administration.
āOur patented Pinā¢ Platform enables practically limitless combinations of effector mechanisms and targeting ligands, building new and innovative therapies without need for drug discovery, with unrivalled efficacy, safety and economics.ā
Alan Cookson
CEO of CYTEA BIO
